Sumitomo Pharma Co.,Ltd. (4506.T) Financial Statements

Income statement

Metric	TTM	2026	2025	2024	2023
Revenue
Total Revenue	453.3B	453.3B	398.8B	314.6B	555.5B
Cost of Revenue	44.1B	196.4B	153.4B	126.6B	178.9B
Gross Profit	63.9B	256.9B	245.4B	188.0B	376.6B
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	35.7B	162.6B	180.6B	429.5B	373.3B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	366.0M	1.1B	3.6B	8.1B	1.7B
Total Operating Expenses	36.0B	163.6B	184.2B	437.7B	375.0B
Cost and Expenses	346.0B	346.0B	370.0B	669.4B	632.5B
Operating Income (EBIT)	107.3B	107.3B	28.8B	(354.9B)	(77.0B)
Non-Operating
Interest Income	585.0M	3.2B	2.3B	36.0B	32.2B
Interest Expense	9.1B	10.2B	13.5B	4.3B	3.2B
Net Interest Income	(8.5B)	(7.0B)	(11.2B)	31.7B	29.1B
Other Non-Op Income/Expense	1.3B	55.8B	18.4B	7.5B	53.3B
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	11.9B	100.3B	17.6B	(323.1B)	(47.9B)
Income Tax Expense	726.0M	(6.5B)	(6.0B)	(8.2B)	48.8B
Bottom Line
Net Income	106.9B	106.9B	23.6B	(315.0B)	(74.5B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	106.9B	106.9B	23.6B	(314.9B)	(96.7B)
Per Share
Basic EPS	¥269	¥269	¥59	(¥793)	(¥188)
Diluted EPS	¥269	¥269	—	—	—
Revenue Per Share	¥1,141	¥1,141	¥1,004	¥792	¥1,398
Shares
Basic Shares Outstanding	397.3M	397.3M	397.3M	397.3M	397.3M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	25.6B	128.1B	54.4B	(317.1B)	(35.7B)
D&A	5.2B	20.8B	25.6B	37.8B	41.3B
EBIT	107.3B	107.3B	28.8B	(354.9B)	(77.0B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026